SPRIND’s modeling shows that broad-spectrum antiviral drugs could reduce severe infections and deaths to less than 1% of what we saw with COVID-19. Read More
SPRIND’s modeling shows that broad-spectrum antiviral drugs could reduce severe infections and deaths to less than 1% of what we saw with COVID-19. Read More